SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (5384)9/22/1998 10:00:00 PM
From: Elmer  Read Replies (1) of 6136
 
Hi Izzy,
On VRTX stock price, I think it's doing what AGPH's stock did when it filed for its NDA with the FDA. About six weeks after the filing, AGPH's stock went from $65 to $100. VRTX was also very depressed because an analyst with DLJ suggested that GLX was going to return the rights to the PI to VRTX after the conference last summer that had everybody thinking that DuPont's product would kill demand. So the announcement yesterday by GLX, takes that risk out of the stock.

Also, there has been some suggestion that VRTX's PI passes through the brain barrier which is viewed as advantageous. But I don't know whether it's important or not. If GLX is accepted and presents at the conference Thurs., this could boost the stock further. While I don't know this for a fact, the stock may have popped today because abstracts were sent out. We will see soon.

Finally, VRTX has a multiple drug resistance product in Phase II. Results will be out in Nov. or Dec. and the street doesn't think it works.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News